Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
adIVO: Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
NCT07260175Phase 2Recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Nov 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivosidenib in cholangiocarcinoma (CCA), sponsored by Institut für Klinische Krebsforschung. Started Nov 2025; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07260175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07260175.